XBIT (XBiotech) Cyclically Adjusted Book per Share: $7.24 (As of Mar. 2026)


XBIT XBiotech Inc XBIT
32 GF Score
Price $2.30
! 2 Warning Signs
View Full Analysis

What is XBiotech Cyclically Adjusted Book per Share?

XBiotech XBIT -0.43% 32 Cyclically Adjusted Book per Share is $7.24 as of Mar. 2026. GuruFocus rates XBIT with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

XBiotech's adjusted book value per share for the three months ended in Mar. 2026 was $4.429. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.24 for the trailing ten years ended in Mar. 2026.

During the past 12 months, XBiotech's average Cyclically Adjusted Book Growth Rate was 3.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-02), XBiotech's current stock price is $2.30. XBiotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $7.24. XBiotech's Cyclically Adjusted PB Ratio of today is 0.32.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of XBiotech was 1.49. The lowest was 0.32. And the median was 0.61.


XBiotech  (NAS:XBIT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

XBiotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.30/7.24
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of XBiotech was 1.49. The lowest was 0.32. And the median was 0.61.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


XBiotech Cyclically Adjusted Book per Share Related Terms


XBiotech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for XBiotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech Cyclically Adjusted Book per Share Chart

XBiotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 6.37 6.79 7.09

XBiotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.97 7.04 7.10 7.09 7.24

XBIT vs ACRV, EXOZ, BYSI: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, XBiotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XBiotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where XBiotech's Cyclically Adjusted PB Ratio falls into.


XBIT
32GF Score
XBiotech Inc XBIT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XBiotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XBiotech's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.429/330.2130*330.2130
=4.429

Current CPI (Mar. 2026) = 330.2130.

XBiotech Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.553 241.018 3.498
201609 2.208 241.428 3.020
201612 1.810 241.432 2.476
201703 2.336 243.801 3.164
201706 2.065 244.955 2.784
201709 1.895 246.819 2.535
201712 1.698 246.524 2.274
201803 1.588 249.554 2.101
201806 1.438 251.989 1.884
201809 1.310 252.439 1.714
201812 1.153 251.233 1.515
201903 1.025 254.202 1.331
201906 1.693 256.143 2.183
201909 1.574 256.759 2.024
201912 18.199 256.974 23.386
202003 12.029 258.115 15.389
202006 11.889 257.797 15.229
202009 11.844 260.280 15.026
202012 11.897 260.474 15.082
202103 11.743 264.877 14.640
202106 11.610 271.696 14.111
202109 9.019 274.310 10.857
202112 8.850 278.802 10.482
202203 8.724 287.504 10.020
202206 8.404 296.311 9.366
202209 8.043 296.808 8.948
202212 7.898 296.797 8.787
202303 7.783 301.836 8.515
202306 7.526 305.109 8.145
202309 7.315 307.789 7.848
202312 7.190 306.746 7.740
202403 6.873 312.332 7.266
202406 6.457 314.175 6.787
202409 6.303 315.301 6.601
202412 5.978 315.605 6.255
202503 5.731 319.799 5.918
202506 5.676 322.561 5.811
202509 5.480 324.800 5.571
202512 4.603 324.054 4.690
202603 4.429 330.213 4.429

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $7.24 mean?
XBiotech (XBIT) has a Cyclically Adjusted Book per Share of $7.24 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on XBiotech and its competitors.
Is XBiotech's Cyclically Adjusted Book per Share too high?
XBiotech's current Cyclically Adjusted Book per Share is $7.24. Overall, XBiotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does XBiotech's Cyclically Adjusted Book per Share compare to ACRV and EXOZ?
XBiotech's Cyclically Adjusted Book per Share of $7.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on XBiotech and its competitors. XBiotech's current Cyclically Adjusted Book per Share is $7.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
XBiotech (XBIT) has a current Cyclically Adjusted Book per Share of $7.24. The current Cyclically Adjusted Book per Share is $7.24. XBiotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For XBiotech (XBIT), the current Cyclically Adjusted Book per Share is $7.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XBiotech Business Description

Other Exchanges 4XB:Germany
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
32GF Score

Get the complete analysis for XBIT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.30
Price